Updated:
GRAIL
GRAIL was founded in 2015 by Illumina veterans seeking to crack multi-cancer early detection from a blood draw.
GRAIL
GRAIL was founded in 2015 by Illumina veterans seeking to crack multi-cancer early detection from a blood draw. The company emerged from stealth with $100M in Series A funding and quickly became the most heavily funded liquid-biopsy startup. GRAIL’s strategy centers on its Galleri test, which uses DNA methylation patterns in circulating cell-free DNA to flag signals from multiple cancer types. The firm runs its CLIA-certified labs across Menlo Park, San Diego, and Shenzhen, and pursues partnerships with health systems, employers, and payers — it signed a multiyear agreement with the U.K. National Health Service in 2021 for a large-scale clinical trial. GRAIL also invests heavily in AI/ML for assay refinement and data interpretation. Illumina, the sequencing giant, acquired GRAIL for $8B in 2021, then spun it back out as an independent company in June 2024 under CEO Josh Ofman, a physician and former Illumina executive. The separation followed FTC regulatory pressure and a declining valuation, reported at roughly $1–2B at exit. GRAIL continues to add partnerships and broaden insurer coverage for Galleri. A structural differentiator is GRAIL’s singular product focus: no other company has run a trial of this scale — over 40,000 participants — for a pan-cancer blood test. Its regulatory posture as a marketed LDT (laboratory-developed test) under FDA review sets it apart from software-only diagnostics or single-cancer assays.
General information
Firm type
other
Year founded
2015
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Menlo Park
Corporate office
Menlo Park, CA, United States
Additional offices
San Diego, CA, United States · Princeton, NJ, United States · Palo Alto, CA, United States · Kenilworth, NJ, United States · Shenzhen, China
Principals
Josh Ofman
Chief Executive Officer
Sector focus
Frequently asked questions
Who runs investment decisions at GRAIL?
GRAIL is an operating company, not an investment vehicle. Strategic decisions are made by CEO Josh Ofman and the board of directors (per public record, 2024).
Is GRAIL still backed by Illumina?
No. Illumina spun out GRAIL as an independent company in June 2024, after acquiring it in 2021. Illumina no longer holds a controlling stake (per Illumina press release, June 2024).
What cancer types does Galleri detect?
The Galleri test detects a shared signal from over 50 cancer types, over 45 of which lack standard screening. It is marketed as a laboratory-developed test under CLIA (per GRAIL official communications).
How is GRAIL's AI/ML work structured?
GRAIL uses machine learning to analyze DNA methylation patterns from a single blood draw. Its algorithms classify the presence and tissue of origin for multiple cancers, refined through a clinical trial of over 40,000 participants (per GRAIL official communications).
Does GRAIL operate outside the US?
Yes. GRAIL has a lab in Shenzhen, China, and has conducted a major clinical trial with the U.K. National Health Service. Its corporate headquarters is in Menlo Park, CA (per public record).
What is the regulatory status of Galleri?
Galleri is available as a CLIA-validated laboratory-developed test. GRAIL is pursuing FDA approval via a Premarket Approval (PMA) pathway, with a pivotal study underway (per GRAIL official communications).
Does GRAIL take outside investment?
GRAIL raised over $2B in equity and debt from investors during its pre-acquisition phase. Post-spinout, it operates as a standalone company and may consider future rounds, but no current funding round is publicly disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: